Have questions about KLOW ?

Text us: 303-204-2469   720-499-6468

Out of stock

KLOW

Recovery Compound

Quantity

Title

Discount

Buy 1

0%

Buy 2

3%

Buy 3

5%

Buy 4

10%

Research Use Only

These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.

What is the KLOW blend?

The “KLOW” blend is a research peptide blend studied for its potential role in cellular recovery, inflammation modulation, and tissue support. It includes TB-500, BPC-157, GHK-Cu, and KPV—peptides commonly explored for their effects on wound healing, immune signaling, and epithelial restoration. Research applications often focus on post-injury models and peptide-driven recovery pathways.

Frequently asked questions

Products from DTC Peptides do not include usage instructions, as they are strictly for in vitro research and prohibited by law for human or animal use. Misuse or unlawful application will result in permanent denial of service.
Each 80mg vial contains 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500, and 10mg KPV.
Peptides are supplied as lyophilized powder. They do not come reconstituted, and any extra supplies must be sourced separately for research applications.
In lyophilized powder form, peptides stay stable for up to 2 years. After reconstitution, it should be refrigerated and is generally stable for up to 2 months.

Made in the USA

Quality controlled from start to finish. No outsourcing.

Need Help?

Send us a message.

KLOW Blend Overview

The KLOW Blend combines GHK-Cu, BPC-157, TB-500, and KPV into a single formulation studied for its potential influence on cellular repair and systemic regulation. In laboratory and preclinical models, these peptides have been investigated for their effects on tissue remodeling, angiogenesis, inflammatory modulation, and extracellular matrix activity. Together, they provide a platform for exploring synergistic pathways in regeneration, immune signaling, and vascular biology.

Pickart L. & Margolina A. 2018

History

The KLOW Blend draws on several decades of peptide research, bringing together compounds that have been investigated in diverse experimental contexts. GHK-Cu, first identified in human plasma in the 1970s, has been studied for its potential roles in gene expression and wound repair models. BPC-157, synthesized in the 1990s as a gastric protein fragment analog, has been explored in relation to angiogenic and reparative processes. TB-500, a synthetic fragment of thymosin beta-4 originating from thymus peptide research of the 1960s, has been examined in studies of angiogenesis and cellular migration. KPV, a C-terminal fragment of α-MSH, has been evaluated for its anti-inflammatory and immunomodulatory activity in research settings. Collectively, these peptides represent areas of ongoing scientific investigation into regenerative biology, vascular pathways, and immune signaling. The KLOW Blend is intended for research use only and is not for human or animal therapeutic applications.

Maquart F.X. et al. 1988

GHK-Cu Structure

CAS #: 49557-75-7

Molecular Formula: C₁₄H₂₄CuN₆O₄

Molecular Weight: 340.9 g/mol

PubChem ID: 5311476

BPC-157 Structure

CAS #: 137525-51-0

Molecular Formula: C₁₄H₂₄CuN₆O₄

Molecular Weight: 340.9 g/mol

PubChem ID: 5311476

TB-500 Structure

CAS #: 77591-33-4

Molecular Formula: C₂₁₂H₃₅₀N₅₆O₇₈S

Molecular Weight: 4963.5 g/mol

PubChem ID: 16132321

KPV Structure

CAS #: 3061-91-6

Formula: C₁₆H₂₈N₆O₅

Molecular Weight: 388.4 g/mol

PubChem ID: 16129619

Research Findings

The KLOW Blend, which combines GHK-Cu, BPC-157, TB-500, and KPV, has been studied in structural, vascular, dermatological, and systemic models. Research highlights activity in collagen formation, extracellular matrix remodeling, angiogenesis, wound closure, and inflammation modulation. The inclusion of KPV further supports immune regulation and anti-inflammatory pathways, expanding the experimental scope of this blend in preclinical settings.

Key Areas of Research:

• Structural: collagen, matrix, connective tissue

• Vascular: angiogenesis, nitric oxide, remodeling

• Dermatological: wound closure, skin, hair growth

• Systemic: inflammation, immune balance, recovery

Together, these findings suggest broad experimental potential for the KLOW Blend across multiple biological pathways. By combining structural support, vascular and dermatological activity, and immune regulation, the KLOW Blend provides a versatile platform for research into regeneration, tissue repair, and systemic resilience in laboratory models.

Sikiric P. et al., 2020

Text us, our dedicated team is here to help

Reach out and get a response within minutes.

You are not allowed because you are under 21.